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Abstract 
Ethnopharmacological relevance: 
 According to Saharian traditional medicine, Anvillea radiata Coss. & Dur. (Asteraceae) has 
been valued for treating a variety of ailments such as gastro-intestinal, liver and pulmonary 
diseases, and has gained awareness for its beneficial effect on postprandial hyperglycemia. 
However, to best of our knowledge, no detailed study of the antidiabetic curative effects of this 
plant has been conducted yet. 
Aim of the study: 
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 To determine the hypoglycemic and antidiabetic effect of dietary supplementation with Anvillea 
radiata extracts on high-fat-diet (HFD)-induced obesity and insulin resistance in C57BL/6J mice 
in relation with antioxidant, anti-inflammatory, pancreatic beta-cells and skeletal muscle 
protection, and digestive enzyme inhibiting properties. 
Materials and methods: 
 Six extracts (water soluble and organic) from aerial parts of the plant were analyzed 
phytochemically (total phenolic and flavonoid content) and screened for in vitro superoxide (by 
chemiluminescence) and hydroxyl radical (by electron paramagnetic resonance spin-trapping) 
scavenging, antioxidant (DPPH, TRAP and ORAC assays), xanthine oxidase, metal chelating, α-
amylase and α-glucosidase inhibitory property, and protective effects on copper-induced 
lipoprotein oxidation. Then selected hydroalcoholic and aqueous extracts were assessed for 
toxicity in normal human lung fibroblasts and A549 cancer cells using FMCA and MTT assays. 
Two water-soluble extracts having the best overall properties were assessed for their (i) 
protective effect at 115 µg/mL on metabolic activity of rat insulinoma-derived INS-1 cells 
exposed to hyperglycemic medium, and (ii) acute hypoglycemic effect on 16-weeks HFD-
induced diabetic mice. Then diabetic mice were administered HFD supplemented by extracts (up 
to 150 mg/kg/day) for 12 additional weeks using standard diet as control and the antidiabetic 
drug, metformin (150 mg/kg), as positive control. Then the antidiabetic, anti-inflammatory and 
antioxidant activity of extracts were determined. 
Results: 
 Of the highly efficient polyphenolics-enriched hydroalcoholic and ethyl acetate extracts, the 
lyophilized aqueous (AQL) and butanol extracts were not toxic in cells (≤ 400 µg/mL) or when 
given orally in normal mice (≤ 2000 mg/kg), exerted a dose-dependent hypoglycemic action in 
diabetic mice, which was maximal at the dose of 150 mg/kg. Upon administering this dose for 12 
weeks, both extracts significantly ameliorated body weight control capacity, recovery of plasma 
glucose and insulin level, reduced oxidative stress in blood, myocardial and skeletal muscles, and 
improved hyperlipidemic and inflammatory status. Moreover, diabetes-related complications 
were optimally ameliorated by oral therapy based on halved doses (75 mg/kg) of a mixture of 
AQL and metformin. 
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Conclusions: 
 Current investigation supports the traditional medicinal usage of Anvillea radiata and suggests 
that both readily accessible and low-cost bio-extracts have the potency to develop an 
antihyperglycemic, antihyperlipidemic and protective agent against beta-cells and muscle 
dysfunction at doses compatible with the common practices of indigenous people for the 
management of metabolic disorders. 
Graphical abstract 
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1. Introduction 
 
 For centuries, plants have been exploited as remedies, the knowledge on their 
pharmacological activities being primarily based on empirical findings. Over the recent past, 
interest in identifying druggable metabolites from plants has also inspired the design of modern 
synthetic lead drugs for the treatment of non-communicable diseases, including cancer, 
cardiovascular disease and diabetes mellitus (Bailey et al., 1989; Gurib-Fakim, 2006). For 
instance, it is estimated that more than 70% of the population in developed or developing 
countries currently use medicinal plants alone or in combination with allopathic drugs (Gurib-
Fakim, 2006; Lesgards et al., 2014) and that almost 80% of diabetics worldwide still depend 
exclusively on herbal folk medicine (Rios et al., 2015). 
 Surveys of traditional Saharian medicines have been conducted with the help of local 
populations, leading to inventories of dozens of indigenous medicinal plants and their therapeutic 
indications (Hammiche and Maiza, 2006; Boudjelal et al., 2013; Fakchich and Elachouri, 2014). 
Notably, Anvillea radiata Coss. & Dur (Asteraceae), which is mainly distributed in northern 
Africa, is used by populations and traditional healers in infusions or decoctions of the leaves and 
flowers to treat a variety of ailments such as chest cold, gastrointestinal, liver and pulmonary 
disorders, and postprandial hyperglycemia (Hammiche and Maiza, 2006; Ghourri et al., 2013; 
Fakchich and Elachouri, 2014).
 
Previous phytochemical reports identified two main families in 
A. radiata aerial parts, i.e., germacranolides such as 9α-hydroxyparthenolide and 8α, 9α-
epoxyparthenolide isolated in chloroform extracts, and a less abundant fraction of phenolics 
(e.g., derivatives of dicaffeoylquinic acid), including flavonoids (both glycosides and aglycones) 
in aqueous/alcoholic extracts (Dendougui et al., 2006; Moumou et al., 2014; Destandau et al., 
2015; Boukhris et al., 2016). Aside from these active compounds, saponins, tannins, fatty acids, 
and various types of secondary metabolites, including sterols, terpenoids, etc. were found in A. 
 5 
radiata extracts using polar solvents (Lakhdar et al., 2013; Hamada and Ladjel, 2015), many of 
them having potential biological and antioxidant activities. Germacranolides from A. radiata 
demonstrated antitumoral, anti-inflammatory and antibacterial properties (Moumou et al., 2014) 
and up to now laboratory investigation of the biological activities of whole material preparations 
of the plant has focused on the antimicrobial (Bammou et al., 2015; Hamada and Ladjel, 2015)
 
and antifungal (Lakhdar et al., 2013) properties of aqueous and organic extracts. 
 Plant-derived phenolics and terpenoids such as those prevailing in A. radiata polar extracts 
are known antioxidants acting by terminating free radical chains and/or inactivating metal ion 
catalysis of lipid peroxidation, and their presence is of great pharmacological and therapeutic 
interest in several pathologies where overproduction of reactive oxygen species (ROS) has been 
implicated (Pietri et al., 1997; Del Rio et al., 2013). In this regard, A. radiata decoctions or as 
dried powder are commonly ingested in Saharian traditional medicine against diabetes 
(Hammiche and Maiza, 2006; Ghourri et al., 2013; Fakchich and Elachouri, 2014), a pathology 
associated with the setting of sustained oxidative stress and altered antioxidant levels (Giacco 
and Brownlee, 2010). This role of ROS formation in the pathogenesis of type 2 diabetes mellitus 
complications such as cardiovascular and renal dysfunction, and neurological damage is well 
established (Meigs, 2010). Antioxidant and antihyperglycemic therapeutic strategies based on 
natural compounds are emerging which can provide long-lasting control of glycemia with 
minimal side effects (Giacco and Brownlee, 2010; Rios et al., 2015). In connection, studies on 
experimental diabetes in animals have reported the hypoglycemic action of extracts or isolated 
flavone constituents in other species belonging to the Asteraceae family, the efficiency being 
however strongly depending on the choice of the model and administration procedure (Bnouham 
et al., 2006). 
 To set up Anvillea radiata extraction procedures allowing for an improved standardization 
of active compounds, the objectives of this study were thus: (i) to determine the phenolic profiles 
in nonpolar vs polar extracts and their associated inhibition properties towards a series of 
determinants of ROS and cytotoxicities in normal and cancer cultured cells; (ii) to assess for the 
first time the in vitro α-amylase and α-glucosidase inhibitory activities of the extracts; (iii) to 
evaluate their protective effect on cultured rat beta-cells exposed to hyperglycemic conditions, 
and (iv) to evaluate the effect of oral administration of two potentially druggable extracts on 
 6 
hyperglycemia, oxidative stress, metabolic and inflammatory biomarkers of type 2 diabetes and 
obesity in a model of high-fat fed C57/BL6J mice. 
 
2. Materials and methods 
 
2.1. Standards, reagents and cell culture media 
 HPLC grade solvents were used throughout, including methanol and ethyl acetate which 
were from Acros Organics (Fisher Scientific, Illkirch, France) and n-butanol and petroleum ether 
(4060°C) which were from VWR Chemicals (Fontenay sous Bois, France). Deionized water 
obtained from a Purelab station (Elga, France) was used throughout. Normal and extract-
containing cell culture media were passed through a 2-µM Millipore filter before use. 2,2'-
Azobis(2-amidinopropane) dihydrochloride (AAPH), allopurinol and phenolic standards (Trolox, 
quercetin, naringenin, gallic, caffeic, ferulic and sinapic acids) were purchased from Acros. 
Phosphate-buffered saline (PBS) and other buffers, xanthine, xanthine oxidase (XO; from 
buttermilk), 2-thiobarbituric acid (TBA), diethylenetriaminepentaacetic acid (DTPA), 3-(4,5-
dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT), hydrogen peroxide (H2O2), 
adenosine triphosphate (ATP), 2-deoxy-D-ribose (deoxyribose), the spin trap 5,5-dimethyl-1-
pyrroline N-oxide (DMPO) and all other reagents were purchased from SigmaAldrich (Saint 
Quentin Fallavier, France). Media for cell culture were from Gibco Life Technologies (Thermo 
Fisher Scientific), including Dulbecco’s modified Eagle’s medium (DMEM), Roswell Park 
Memorial Institute medium (RPMI 1640) and GlutaMax, or Lonza (Arch Water Products, 
Amboise, France), including fibroblast basal medium (FBM) and growth factors (FGM; 
Clonetics). Hypoglycemic drugs metformin hydrochloride (Met; 99.9%, pharmagrade; from 
UniPex Pharmaceuticals, France) and glibenclamide (from TCI Europe, Belgium) were used as 
positive controls in antidiabetic studies. 
 
2.2. Plant material 
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 The aerial parts (flowers and leaves) of Anvillea radiata were collected in april 2013 in the 
area of El Oued, in the Algerian part of Sahara (altitude, 69 m). The main information (local 
name, collected parts of plant, traditional methods of preparation and usual medicinal uses and 
administration) were obtained from local inhabitants having ancestral knowledge of the curative 
properties of the plant. The sample was identified by Prof. N. Khalfallah (Laboratoire de 
Génétique, Biochimie, et Biotechnologies Végétales, Université Frères Mentouri (UFM), 
Constantine, Algeria). A voucher specimen (LBE13/01) has been deposited in the herbarium of 
the Faculty of Natural and Life Sciences at UFM. The plant material was dried at ambient 
temperature in the dark for 30 days and stored in a dry place prior to use. 
 
2.3. Plant material preparation 
 
2.3.1. Lyophilized aqueous extract 
 The dried plant material (10 g) was suspended in 200 mL of hot water and stirred for 30 
min. The resulting extract was filtered, frozen with liquid N2 and lyophilized (Cryotec 
lyophilizer model Cosmos, Saint-Gély-du-Fesc, France) at 80 °C. This lyophilized aqueous 
extract (AQL) was obtained in ~15% w/w yield and was stored at 20 °C until analysis. 
 
2.3.2. Organic extracts 
 A schematic diagram for the preparation of organic extracts of A. radiata is shown in Fig. 1. 
The dried plant material (200 g) was extracted with 1.2 L of methanol for 24 h at room 
temperature. After filtration of the residue the above procedure was repeated twice and the 
combined extracts were evaporated at 37 °C until dryness using a rotary evaporator to give the 
methanol-soluble extract (25.75 g, 12.8% w/w). Then the methanol extract was treated with 300 
mL of hot water to dissolve polyphenols, filtered and the resulting aqueous solution was first 
treated with petroleum ether (PE; 4×100 mL) to remove lipids and then successively partitioned 
with ethyl acetate (4×100 mL), and n-butanol (4×100 mL) according to previous procedures 
(Koleva et al., 2002; Bammou et al., 2015). After rotary evaporation under vacuum the following 
fractions were obtained: PE-soluble extract (1.9 g, 0.95% w/w), ethyl acetate-soluble extract (2.8 
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g, 1.4% w/w), and n-butanol-soluble extract (2.9 g, 1.4% w/w). The residual aqueous layer was 
frozen with liquid N2 and lyophilized to yield the aqueous residual (AR) fraction (12 g, 6% w/w). 
All these extracts were stored at 20 °C until analysis. 
 
2.4. Total phenolic content (TPC) and total flavonoid content (TFC) of extracts 
 
 The TPC of each extract were determined using a reported procedure (Singleton et al., 1999) 
with minor modification. Samples (20 µL) dissolved in methanol at 0.1 mg/mL were mixed with 
100 µL of a solution of the FolinCiocalteu reagent (Sigma-Aldrich; 0.2 N in distilled water), the 
mixtures were vortexed for 5 min and 80 µL of an aqueous sodium carbonate solution (75 g/L) 
was added. After 2 h incubation at room temperature the absorbance of the supernatant was read 
at 760 nm using a UVvisible spectrophotometer. The TPC was evaluated using a gallic acid 
calibration curve in methanol and the results are expressed as milligrams of gallic acid 
equivalents (GAE) per gram of extract weight. 
 The TFC of each extract was determined according to a reported procedure (Ordonez et al., 
2006). Samples (100 µL) dissolved in ethanol at 0.5 mg/mL were mixed with 100 µL of ethanol 
containing 2% aluminium chloride. After 1 h incubation at room temperature the absorbance was 
read at 420 nm. The TFC was evaluated using a rutin calibration curve in ethanol and the results 
are expressed as milligrams of rutin equivalents (RUE) per gram of extract weight. 
 
2.5. HPLC analysis of phenolic compounds 
 
 To separate phenolic compounds a Merck Hitachi system consisting of a LaChrom L-7000 
interface module and a L-7455 photodiode array detector controlled by the EZ Chrome 
chromatography manager software was used. For each fraction (2 mg/mL in methanol), the 
average amounts of phenolic compounds were calculated from standard calibration curves 
obtained at the maximum UV absorbances of flavonoids, hydroxybenzoic and hydroxycinnamic 
compounds, and were quantified as GAE, caffeic acid equivalents (CAE) and RUE per gram of 
extract weight, respectively. 
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 Reverse phase HPLC was carried out at room temperature on a Htec RP-18 column (250 
mm × 4 mm; 5 µm; Macherey-Nagel, France) using a gradient with a flow rate of 0.8 mL/min. 
Gradient: solvent A (0.05% phosphoric acid in water, pH 2.6), solvent B (methanol): 045 min, 
3060% B; 4550 min, 60% B; 5051 min, 30% B; 5157 min, 30% B. 
 
2.6. Antioxidant assays 
 
2.6.1. 2,2-Diphenyl-1-picrylhydrazyl (DPPH) radical scavenging assay 
 For each extract a DPPH assay was carried out using a reported procedure (Alencar et al., 
2008). Aliquots of each extract dissolved in methanol (20660 µg/mL, final concentration) were 
mixed with 200 µL of a fresh DPPH solution (SigmaAldrich; 0.126 mM) in methanol and the 
final volume was adjusted to 300 µL. After stirring the mixtures for 390 min at room 
temperature in the dark the absorbance was monitored at 517 nm on a microplate reader 
(TECAN infinite M200, Switzerland) until a plateau was reached. Percent DPPH scavenged was 
calculated using eq 1 
Inhibition (%) = [100 × (A0A)/A0] (1) 
where A0 is the baseline value for neat DPPH in methanol and A is the absorbance in the 
presence of a given concentration of the tested extract. IC50 values (the concentration resulting in 
50% DPPH scavenging) were calculated (in µg/mL) by non-linear fitting of dose-response 
curves and TIC50 values were derived as the time (in min) required to reach the steady state for a 
concentration equal to IC50. 
 
2.6.2. Total reactive antioxidant potential (TRAP) 
 TRAP was determined in Tris-HCl buffer (0.1 M, pH 7.4) as described (Cassien et al., 2016) 
using fresh stock luminol solutions kept in the dark at 4 °C until use. Peroxyl radicals were 
generated by heating AAPH (150 mM in 10 mL Tris-HCl) at 37 °C for 30 min. Once cooled at 
room temperature, this solution can be used for up to 20 min. In this order, 2 mL of AAPH 
solution, 0.5 mL of luminol solution (13 µM), and 0.5 mL of a Tris-HCl:DMSO (100:1 v/v) 
solution of each extract (0.4−25 µg/mL, final concentration) were added and the mixture was 
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stirred for 20 s at room temperature. Luminescence was recorded at room temperature (Titertek-
Berthold Sirius luminometer, Pforzheim, Germany). In the assay Trolox was the reference and 
the TRAP was obtained by integrating the area under curve (AUC) for sample and blank 
solutions (all reactants except test fraction) and the results are expressed as µmole Trolox 
equivalents (TE) per gram of extract weight or TE (standards). 
 
2.6.3. Oxygen radical absorbing capacity (ORAC) assay 
 The assay was performed in microplates according to modifications of previous methods 
(Dávalos et al., 2004). A fluorescein stock solution (0.821 mM) was prepared in PBS 1X and 
stored at 4 °C. Solutions of AAPH (153 mM) and fluorescein (82.1 nM) in KH2PO4 buffer (100 
mM, pH 7.4) were prepared daily. Samples (25 µL/well) of tested extracts dissolved in buffer 
containing 0.05% v/v DMSO (0.947.5 µg/mL, final concentration) were mixed with 150 
µL/well of fluorescein solution and the mixture was incubated for 10 min at 37 °C. Aliquots of 
AAPH solution (25 µL/well, 19.12 mM, final concentration) were added and the fluorescence 
was recorded at 2-min intervals for 70 min at wavelengths of 485 nm for excitation and 530 nm 
for emission. Blank was made using PBS instead of test fraction. In each assay a calibration 
curve was performed with Trolox (0.412.5 µM) as standard. The ORAC values were calculated 
using the neat AUCs and expressed either as µmole TE per gram of extract weight or TE 
(standards). 
 
2.6.4. Xanthine oxidase inhibition assay 
 Inhibition of XO by the extracts was evaluated in microplates by measuring the inhibition of 
XO-catalyzed formation of uric acid from xanthine as described previously (Cos et al., 1998).
 
Samples (150 µL/well) dissolved in DMSO (18.5−600 µg/mL, final concentration) were added 
to 250 µL/well of a reaction mixture consisting of 25 µL xanthine solution at 50 µM and 25 µL 
EDTA solution at 10 µM, both in PBS (0.2 M, pH 7.5) containing 0.31% v/v DMSO. The 
reaction was started by adding to the mixtures 25 µL/well of XO solution (23.3 mU) in PBS. 
After 30 min incubation at 37 °C uric acid formation was measured at 290 nm. Enzyme was 
omitted in the blank controls and EC50 values (in µg/mL) were determined as the concentration 
that halved uric acid formation in the control. Allopurinol and quercetin were used as standards. 
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2.6.5. Superoxide radical scavenging (O2
-
) capacity 
 The O2
-
 scavenging capacities were assayed in glycine buffer (6.25 mM, pH 10.1) at 25 °C 
according to previous procedures (Cassien et al., 2016). The assay measures inhibition by the 
extracts of lucigenin-derived chemiluminescence produced by the allopurinol/XO O2
-
 generating 
system. Samples (2.4−48 µL) dissolved in glycine buffer:DMSO (1000:1 v/v) at 200 µg/mL 
were diluted in glycine buffer as to reach a final volume of 1.7 mL. To these solutions were 
added 300 µL of allopurinol solution (12.5 µM) and 100 µL of XO solution (0.458 mU/mL), 
both in glycine buffer. The test tube was shaken, inserted in a luminometer, 300 µL of lucigenin 
solution in glycine buffer (2.5 µM) was added and luminescence of the sample was monitored at 
1.2-s intervals for a total period of 4.12 min following lucigenin addition. The O2
-
 scavenging 
activity was calculated against controls (in the absence of extract) from AUCs. The results are 
expressed as IC50 values (in µg/mL). 
 
2.6.6. Metal chelating capacity (MCC) 
 The MCC of the extracts was measured in microplates according to a published method 
(Ambigaipalan et al., 2016) with some modification. Samples (200 µL/well) dissolved in 
methanol at 0.3–2.4 mg/mL were mixed with 10 µL/well of aqueous ferrous chloride (2 mM). 
The mixture was then reacted with 40 µL/well of 5 mM aqueous 3-(2-pyridyl)-5,6-bis(4-
phenylsulfonic acid)-1,2,4-triazine (ferrozine; Sigma–Aldrich) for 10 min at room temperature 
under vigorous stirring. The absorbance was read at 562 nm and a calibration curve was 
constructed using EDTA as standard. Percent inhibition of Fe
2+
ferrozine complex was 
calculated using eq 1 where A0 is the absorbance of the control (water instead of extract). The 
results are expressed as micromoles of EDTA equivalents (EDTAE) per gram of extract weight. 
 
2.6.7. Inhibition of deoxyribose degradation 
 The ability of AQL, butanol extract and AR fraction to inhibit the formation of TBA reactive 
substances resulting from the degradation of deoxyribose by Fenton-derived hydroxyl radical 
(HO

) was evaluated in a colorimetric assay according to a reported method (Bailey et al., 2014). 
When ferrous ions (formed by reducing Fe
3+
 by ascorbate) are used in the Fenton reagent, adding 
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an excess EDTA in the system allows determining the direct HO

 scavenging effect of the extract 
(radiomimetic assay) while omitting EDTA in the mixture will measure the capacity of the 
fraction to interact with site-specific HO

-induced damage to deoxyribose (Aruoma et al., 1987; 
Halliwell et al., 1987).The reaction mixture (1 mL, final volume) contained the tested compound 
(500 µL) dissolved in water at 0.0250.25 mg/mL and aliquots (100 µL) of the following 
reagents dissolved in KH2PO4 buffer (20 mM, final concentration; pH 7.4): deoxyribose (2.8 
mM), FeCl3 (100 µM), EDTA (100 µM) or buffer, H2O2 (1 mM) and ascorbate (100 µM). After 
incubating the mixtures for 1 h at 37 °C TBA (0.5 mL, 1% v/v in 50 mM NaOH) and acetic acid 
(0.5 mL) were added and the mixture was heated at 100 °C for 15 min. After cooling, absorbance 
was read at 532 nm (A532) against a corresponding blank not containing FeCl3. Mannitol (1−10 
mM) was used as the reference. Percent inhibition of deoxyribose degradation by the extract in 
the presence or absence of EDTA was calculated using eq 1 where A0 is the absorbance of the 
control (buffer instead of fraction) and A is the absorbance in the presence of a given 
concentration of the compound. Control assays in which deoxyribose or Fenton reagents were 
omitted, or test extracts were added after incubating deoxyribose with the Fenton reagents, but 
before addition TBA showed no interference with the assay. 
 
2.6.8. Electron paramagnetic resonance (EPR) spin-trapping analysis 
 Using EPR spectrometry following reported procedures (Alencar et al., 2009; Bailey et al., 
2014),
. 
HO

 scavenging activity of selected extracts was determined by measuring the dose-
dependent inhibition of its DMPO spin adduct at room temperature. Aliquots of tested extracts 
(0.01−10 mg/mL, final concentration) dissolved in KH2PO4 buffer (20 mM; pH 7.4) containing 
DTPA (1 mM) and DMPO (5 mM) were incubated for 80 s with a mixture of H2O2 (0.5 mM) 
and FeSO4 (0.5 mM). Samples were immediately placed into glass capillaries and X-band (9.81 
GHz) EPR spectra were recorded on a Bruker ESP 300 instrument (Karlsruhe, Germany) using 
the following parameters: modulation frequency, 100 kHz; micro-wave power, 10 mW; sweep 
width, 0.07 mT; field axis resolution, 2048 points; receiver gain, 8×10
3
; modulation amplitude, 
0.05 mT; time constant, 5.12 ms and scan rate, 0.33 mT/s. The EPR signal intensities I and I0 
(buffer instead of test fraction) were quantitated by double integration of the simulated spectra as 
described (Bailey et al., 2014). Additionally, the relative scavenging rate constants were 
 13 
estimated by comparing the slopes of I0/I against concentration linear regression curves 
according to a previous method (Finkelstein et al., 1980). 
 
2.7. Inhibition of carbohydrate hydrolyzing enzymes 
 All assays described below were carried out starting from stock solutions at 200 mg/mL 
dissolved in pure distilled water (AQL and AR fraction) or in the presence of 4% v/v DMSO 
(other extracts). In the latter case the final DMSO concentration in the tested samples was < 1% 
and did not interfere with the assay (not shown). Porcine pancreatic α-amylase (EC 3.2.1.1, type 
VI-B), α-glucosidases from Saccharomyces cerevisiae (SC; EC 3.2.1.20, type I), rat intestinal 
acetone powder (RIP), 2-chloro-4-nitrophenol-α-D-maltotrioside (CNPG3) and p-nitrophenyl-α-
D-glucopyranoside (pNPG) were purchased from SigmaAldrich. Porcine pancreatic α-amylase 
assay was performed in microplates using CNPG3 as substrate as described (Gella et al., 1997) 
and the two α-glucosidases assays were performed in using pNPG as substrate according to Oki 
et al. (1999) with slight modifications (Supplementary methods). 
 
2.8. Inhibition of Cu
2+
-induced LDL oxidation 
 
 Fresh plasma was derived from normolipidic healthy volunteers after informed consent and 
LDL was isolated within 1 h after sample collection to obtain an albumin-free LDL preparation 
according to Miranda et al. (2000). Inhibition of LDL oxidation by extracts was then assayed in 
microplates by incubating at 37 °C LDL solutions (50 µg protein per mL) in PBS in the presence 
of CuSO4 (2 µM) and extracts dissolved in ethanol as to reach a final concentration ranging 550 
µg/mL and a final volume of 0.2 mL/well. LDL oxidation was measured by continuously 
monitoring for 6 h conjugated diene hydroperoxide formation at 234 nm against appropriate 
blanks (PBS instead of LDL and cupric sulfate) for background correction. After 6 h incubation, 
the content of each well was added to a mixture of trichloroacetic acid and TBA (1% in 0.5% 
NaOH), the samples were heated at 90°C for 20 min, then centrifuged and the amount of 
thiobarbituric acid-reactive substances (TBARS) was measured at 534 nm with a microplate 
reader. 
 
 14 
2.9. Cell culture and cytotoxicity assays 
 
 The human lung cancer cell line A549 (CCL-185, from ATCC, LGC Standards) and normal 
human lung fibroblasts (NHLF, from Lonza) were routinely maintained in (DMEM + GlutaMax) 
and (FBM + FGM), respectively as described (Cassien et al., 2016). After reaching 90% 
confluence cells were harvested for subculturing. The cells were trypsinized, seeded in 96-well 
microplates (density, 2.5×10
4
 cells/well) and incubated in humidified atmosphere with 5% CO2 
at 37 °C to reach around 80% confluence in appropriate medium. The medium was renewed and 
cells were exposed for 48 h in the presence of extracts (5–500 µg/mL) or 0.2% DMSO in 
medium. After 48 h cells were washed two times with PBS 1X (+/+) for cytotoxicity analysis. 
 Rat pancreatic INS-1E beta-cells were cultivated at 37 °C and 5% CO2 in RPMI 1640 
medium containing glucose (11 mM), fetal bovine serum (10%), glutamine (2 mM), sodium 
pyruvate (1 mM), HEPES (10 mM), β-mercaptoethanol (0.05 mM), penicillin and streptomycin 
according to procedures previously established (Merglen et al., 2004). Cells were then exposed 
to medium containing high (25 mM) or normal (5 mM) glucose concentration for 84 h in 96-well 
plates in the presence of extracts (2–200 µg/mL) or 0.1% DMSO in medium. Medium was 
renewed every day until analysis of viability, metabolic activity and apoptosis (see below). 
 Cytotoxicity was evaluated by two complementary assays performed according to described 
procedures, i.e., a fluorometric microculture cytotoxicity assay (FMCA; see Cassien et al., 2016), 
and the MTT assay (Culcasi et al., 2012). Intracellular ATP content, an index of metabolic 
activity, was assayed using a luciferin-luciferase reagent (Biofax A
®
; Yelen, Ensuès la Redonne, 
France; http://www.yelen-analytics.com). Apoptosis was evaluated by assaying caspase-3 
activity of cell lysates using a commercial fluorescence microplate kit assay (Fischer Scientific, 
France). These procedures are detailed in the Supplementary methods section. 
 
2.10. Animals and study design 
 
 Standard diet (SD; 11% energy by fat) and high-fat diet (HFD, 60% energy by fat) were 
purchased from Safe (Augy, France). All diets contained 20% proteins. Animal care and 
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experimental procedures were performed according to the rules of the European Union Council 
(Revised Directives 2010/63/EU). This protocol was subjected to the scrutinity of the local 
Animal Research Ethics Committee and was approved for the project FEDER-AdiabaOx (2008, 
N° 13851). Aix Marseille University and the CNRS have a license for animal housing and 
experimentation (agreement C13-055-06) and the study was under the supervision of a vet at the 
CNRS. One hundred and twenty-eight 4 weeks-old female C57BL/6J mice were purchased from 
CERJ (Janvier Labs, Le Genest St Isle, France) and maintained under conventional conditions 
with controlled temperature (22 ± 3 °C) and a 12 h light/dark cycle and access to food and water 
ad libitum. An enriched environment, by using wheels, tunnels and toys, was given to promote 
physical and social activity. 
 After one week acclimatization mice were randomly assigned to three experimental 
protocols described in the following. A first protocol examined the acute oral toxicity of AQL 
and butanol extract at 2000 mg/kg on 16-weeks SD animals (n = 4/group) according to the 
procedure of Yamanaka et al. (1990). Extracts, dissolved in a suspension of 0.5% aqueous 
carboxymethyl cellulose (as vehicle), were given orally in the limit of 0.1 mL/10 g body weight. 
A second protocol consisted of a dose-response study of the acute hypoglycemic activity of the 
extracts on 16-weeks HFD animals in comparison with glibenclamide (n = 6/group) as detailed 
below. In a third series of studies the long-term antidiabetic and antihyperglycemic effects of 
extracts were evaluated on the remaining 84 mice which were randomly divided into six 
experimental groups (n = 12): controls given SD for 28 weeks, HFD group (given HFD for 28 
weeks), [HFD+AQL] group, given HFD for 16 weeks, followed by HFD supplemented with 
AQL (150 mg/kg) for 12 weeks; [HFD+AQL75] group, given HFD for 16 weeks, followed by 
HFD supplemented with AQL (75 mg/kg) for 12 weeks; [HFD+n-BuOH] group, given HFD for 
16 weeks, followed by HDF supplemented with butanol extract (150 mg/kg) for 12 weeks; 
[HFD+ Met] group, given HFD for 16 weeks, followed by HFD supplemented with metformin 
(150 mg/kg) for 12 weeks and [HFD+Met75+AQL75] group, given HFD for 16 weeks, followed 
by HFD supplemented with a mixture of metformin and AQL (both at 75 mg/kg) for 12 weeks. 
Weekly weights measurements and daily estimates of food intake and clinical signs of suffering, 
weight loss and moribundity were recorded. At weeks 16 (before incorporation of extracts in the 
food) and 28, blood samples were collected from tail vein under local anaesthesia induced by 
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0.25% lidocaine application in ointment. Blood glucose concentration was measured using a 
commercial whole-blood glucose auto analyser (Freestyle Optium Neo, Abbott). 
 
2.11. Acute hypoglycemic activity of extracts 
 
 In this series of experiments single doses of AQL or butanol extract (25, 75, 150 and 250 
mg/kg), or glibenclamide (15 mg/kg) dissolved in vehicle (see above) were given orally through 
a thin flexible cannula. Glucose concentration was monitored in blood samples (5 µL) collected 
from tail vein at 0, 0.5, 1, 3 and 4 h after administration. Blood glucose concentration was 
measured by a commercial whole-blood glucose auto-analyzer. 
 
2.12. Oral glucose tolerance test (OGTT) in long term-treated mice 
 
  At the end of 28 weeks treatments, the OGTT was performed on n = 6 animals/group 
fasted for 8 h beforehand. A thin cannula was inserted orally and allowed the administration to 
each animal of 3 g/kg glucose solution (20% w/v in normal saline solution, Laboratoire 
Lavoisier, France) in the limit of 0.1 mL/10g body weight. Tail blood (6 µL) was collected at 0, 
20, 40, 60, 90 and 120 min after 0.25% lidocaine application in ointment. Blood glucose 
concentration was measured, a curve over time was generated and the AUC was calculated. 
 Following the OGTT study, mice were maintained on their respective diets for five 
additional days, then fasted overnight and deeply anesthetized using sevoflurane (24%) 
delivered with a mixture O2/air in an anaesthetic chamber (Abbott, Rungis, France) prior to 
sacrifice by cervical dislocation. 
 Blood was withdrawn by orbital cardiac puncture and immediately assayed for reduced 
glutathione (GSH) and oxidized glutathione (GSSG) levels using a commercial glutathione assay 
kit (Caymann Chemical, Bertin Pharma, France). Samples of blood hemolyzates were used for 
hemoglobin (Hb) and glycosylated hemoglobin (HbA1C, expressed as percentage of total Hb 
content) determination as described (Dey et al., 2015). Plasma samples were isolated by 
centrifugation (1650g for 15 min at 3 °C) and stored at 80 °C for further analysis of glucose and 
 17 
insulin levels, and for assaying protein carbonyls and inflammatory markers (see below). Tissues 
and organs were rapidly dissected out, washed with saline and stored at 80 °C for further 
analysis. 
 
2.13. Plasma glucose, insulin and lipid metabolism, and protein carbonyls assay 
 
 Plasma concentrations of total proteins, triglycerides, total cholesterol and glucose were 
assayed using commercially available assay kits (Biolabo Reagents, Maisy, France). Plasma 
insulin concentrations were measured in blood collected on EDTA using a mouse insulin enzyme 
immunoassay kit (SPI bio, Bertin Pharma, France). Glycogen and triglyceride contents were 
assayed in liver tissues using commercial assay kits (Caymann Chemical). Plasma protein 
carbonyls were assayed using a fluorimetric method based on derivatization with 7-hydrazino-4-
nitrobenzo-2,1,3-oxadiazole (NBDH; Sigma−Aldrich) according to Stocker et al. (2015). For 
details see the Supplementary methods section 
 
2.14. Inflammatory biomarkers  
 
 The plasma levels of leptin, and cytokines interleukin-6 (IL-6), monocyte-chemoattractant 
protein 1 (MCP-1) and tumor necrosis factor-α (TNF-α) were determined by commercial 
multiplex assay kit (RECYTMAG-65K; Milliplex Map, Merck, France) on a Magpix unit 
coupled to a xPONENT 4 software (Luminex Corporation) at the CIPHE (Centre de Luminy, 
Marseille). Plasma samples on EDTA were diluted with the kit solution after two freeze/thaw 
cycles (1:1 v/v). Determination of biomarkers concentrations (pg/mL) were drawn from 
experimental curves reporting mean fluorescence intensity (MFI) as a function of concentration. 
 
2.15. NADPH oxidase activity in heart ventricular and sketetal muscle 
 
 NADPH oxidase-triggered O2
-
 production in heart ventricular and skeletal muscle tissue 
was monitored by chemiluminescence in presence of NADPH according to Yokota et al. (2009). 
Briefly, freshly excised heart and hindlimb muscle tissue were snap-frozen with liquid N2 and 
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homogenized in buffer containing 250 mM sucrose and 10 mM HEPES. After centrifugation 
(12000g, 10 min at 3 °C), 5 μL of the lysate was mixed in each well with 200 μL buffer 
containing (in mM): NaCl (98), NaHCO3 (25), KCl (4.7), KH2PO4 (1.5), MgSO4 (1.2), glucose 
(11) and HEPES-Na (20). Chemiluminescence was monitored after addition of 5 μM lucigenin 
and 100 μM NADPH for starting the reaction. In all groups, control experiments were performed 
in the presence of the cell-permeable O2
-
 scavenger 4,5-dihydroxy-1,3-benzene-disulfonic acid 
(Tiron, 20 mM) or the flavoprotein inhibitor diphenyleneiodonium (DPI, 10 μM). 
 
2.16. Statistical analysis 
 
 Statistical analyses of the data were performed using GraphPad Prism 5 software (La Jolla, 
CA, USA). The results are presented as mean ± SD or SEM for the indicated number of 
independent experiments. Correlations among data from antioxidant assays were calculated 
using Pearson's correlation (r²) coefficients. In biological experiments evaluation of statistical 
significance was conducted by Mann-Whitney test when appropriate, or one-way analysis of 
variance (ANOVA) followed, if significant (P < 0.05), by a posteriori Newman-Keuls or 
Tukey’s tests. Differences between groups were considered significant when P < 0.05. 
 
3.  Results and discussion 
 
3.1. TPC, TFC and HPLC analysis 
 
 Phenolic compounds are antioxidant phytochemicals with well-documented beneficial health 
effets (Del Rio et al., 2013) and in desert/steppic plants such as A. radiata they are thought to 
provide enhanced protection against harsh environmental oxidative stress conditions. To increase 
the TPC of AQL obtained by lyophilization of a hot water extract of aerial parts of the plant 
similar to traditional infusion/decoction, a multistep organic extraction procedure first using 
methanol, followed by a three-step partitioning of aqueous phase with PE, ethyl acetate and n-
butanol was carried out (Fig. 1). The TPC, TFC and TFC/TPC ratio of AQL, methanol extract 
and its derived fractions are summarized in Table 1 (left panel). The data demonstrated a high 
 19 
content of phenolics and flavonoids for AQL and methanol extract that fell in the middle range 
of values reported for hydroalcoholic extracts of A. radiata (e.g., 57 mg GAE/g in Hamada and 
Ladjel (2015) or 100200 mg GAE/g in Bammou et al. (2015)), possibly reflecting geographical 
or seasonal variability, or differences in plant drying procedures. The marginal differences found 
between aqueous and methanol extracts regarding TPC and TFC are not surprising because these 
solvents can dissolve almost equally a large portion of polar phenolic compounds (Daneshfar et 
al., 2008). However using methanol extract as starting material for further fractionation was 
considered more pertinent since it significantly favoured the recovery of flavonoids, i.e., a 
4075% increase in the TFC/TPC ratio across extracts was recorded (Table 1, left panel). As 
expected, the ethyl acetate and butanol extracts showed the highest TPC and TFC compared to 
the methanol extract. Recently, using a similar water partition procedure with ethyl acetate and 
n-butanol led to optimized TPC from hexane extracts of Rhododendron anthopogonoides (Jing et 
al., 2015). Owing to the weakest TPC and TFC recovered in the PE and AR fractions, the results 
indicated that the total phenolics of the aerial parts of A. radiata could be enriched in the 
hydroalcoholic and ethyl acetate fractions. 
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Fig. 1. Preparation of organic extracts of Anvillea radiata. 
 
 As the TPC and TFC were determined further, identification and quantitation of the 
phenolics profile in the six A. radiata extracts was carried out by HPLC using a diode array 
detector (DAD). Representative chromatograms are displayed in Fig. 2. The 
qualitativequantitative analysis of each extract is presented in Table 1 (right panel). 
Hydroxycinnamic derivatives and flavonoids, which were present in significant amounts in ethyl 
acetate and butanol extracts with yet a quite different range of compounds (Fig. 2), were still 
found in good yields in the starting AQL and methanol extract, while they were recovered in 
weak amounts or even traces in the PE and residual AR fractions. According to their higher 
polarity, hydroxybenzoic derivatives appeared as minor constituents in hydroalcoholic extracts. 
These classes of phenolics were readily identified by comparison with the retention times (tR) 
and UV spectra of authentic standard samples of gallic (tR = 4.2 min) and caffeic (tR = 13.4 min) 
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acids, and rutin (tR = 28.2 min) at maximal absorption wavelengths of 280, 320 and 350 nm, 
respectively. 
 
Fig. 2. HPLC-DAD chromatograms of A. radiata phenolic compounds detected at 280 nm in various 
extracts: AQL, lyophilized aqueous extract; AR, aqueous residual. Peak labels: HB, benzoic acid 
derivatives; HC, hydroxycinnamic acid derivatives; F, flavonoids derivatives. 
 
 AQL and methanol extract showed close HPLC-DAD profiles, only differing by some extra 
flavonoids. The efficiency of the fractionation scheme of A. radiata (Fig. 1) is illustrated by the 
fact that the AR fraction contained only traces of hydroxycinnamic derivatives (Fig. 2). 
Moreover, the butanol fraction retained a flavonoids content of ~40 mg RUE/g, corresponding to 
that reported by Dendougui et al. (2006) who extracted similar quantity of A. radiata dried 
material using methanol. Among the phytochemicals contents, strong correlations were obtained 
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between the TPC and hydroxycinnamic derivatives (r² = 0.956, P < 0.001) or flavonoids (r² = 
0.892, P < 0.01), whereas hydroxybenzoic compounds did not correlate (P > 0.05). 
 
3.2. In vitro antioxidant properties 
 
 Antioxidant activity of extracts was evaluated by a series of assays that differ in their 
endpoints, i.e., the mechanisms implicated and/or targets. 
 
3.2.1. DPPH, ORAC and TRAP 
 The results of the DPPH (performed in methanol and globally measuring free radical 
reducing activity (Ambigaipalan et al., 2016; Foti, 2015) ORAC and TRAP (both performed in 
buffer and measuring scavenging of peroxyl radicals) assays are shown in Table 2. In the DPPH 
assay, where a lower IC50 value indicates increased activity, ethyl acetate and butanol extracts 
exhibited the highest activity (IC50 ~45 µg/mL). The AR fraction and PE extract were 510 times 
less potent and the standard antidiabetic drug metformin was found inactive (IC50 > 500 µg/mL). 
Such a higher DPPH scavenging effect for ethyl acetate and butanol vs methanol extracts has 
been already observed (Benhammou et al., 2009; Jing et al., 2015). In comparison with the 
literature (Bammou et al., 2015), the method developed in the present study for preparing AQL, 
methanol and ethyl acetate extracts of A. radiata significantly improved DPPH scavenging 
activity. An analysis of the relationship between TPC, TFC and DPPH data indicated good 
correlations (P < 0.05) between these parameters, with Pearson's coefficients r² = 0.672 for TPC 
and r² = 0.678 for TFC. The phenolic compounds caffeic acid, quercetin and gallic acid exhibited 
much stronger activities in the DPPH assay, with IC50 values of 4.71 ± 0.05, 1.71 ± 0.39 and 1.26 
± 0.01 µg/mL, respectively. Being a single electron-based reaction with phenoxyl radical 
intermediates, DPPH quenching is favoured in phenolics featuring catechol (as in caffeic acid 
and quercetin) or pyrogallol (as in gallic acid) moieties (Alov et al., 2015; Foti, 2015). This could 
explain the higher activities seen in the ethyl acetate and butanol extracts which are enriched in 
structurally-related hydroxycinnamic constituents (Table 1 and Fig. 2) having known antioxidant 
properties (Shahidi and Chandrasekara, 2010). Consistent, a good correlation was found between 
DPPH data and hydroxycinnamic contents (r² = 0.534, P < 0.05). Finally, TIC50 values were 
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determined to characterize the kinetic behavior of the extracts in DPPH scavenging. According 
to a previous ranking (Sanchez-Moreno et al., 1998), caffeic acid is a rapid scavenger (TIC50 = 
8.8 min), the AQL, ethyl acetate and butanol extracts showed intermediate kinetic properties 
similar to that of gallic acid (TIC50 = 29.8 min), while methanol and PE extracts, and AR fraction 
were the slowest scavengers, comparable to quercetin (TIC50 > 60 min). 
 Antioxidant capacity determined by ORAC and TRAP consistently showed significant 
increase for the ethyl acetate and butanol extracts compared to the initial AQL and methanol 
extract (Table 2). Highly significant correlations were found between ORAC (r² = 0.950; P < 
0.001) or TRAP (r² = 0.821; P < 0.01) and the hydroxycinnamic derivatives contents. The 
correlations remained strong concerning the flavonoids contents, with Pearson's coefficients r² = 
0.893, P < 0.01 for ORAC and r² = 0.832, P < 0.05 for TRAP. Again, metformin was found not 
effective in both TRAP and ORAC assays. 
 
3.2.2. Superoxide radical scavenging and inhibitory effects on prooxidants 
 To limit oxidative stress, inhibiting O2
-
 and/or some biological sources and conditions of 
production could be of relevance for the medicinal usage of A. radiata. The results of XO 
inhibition (by measuring uric acid production according to Cos et al. (1998)), O2
-
 scavenging 
(by a fluorescence method (Cassien et al., 2016)) and MCC determination (by the ferrozine assay 
(Ambigaipalan et al., 2016) performed in methanol) are shown in Table 3. Only AQL, methanol, 
ethyl acetate and butanol extracts demonstrated weak XO inhibitory activities (IC50 > 100 
µg/mL) compared to fairly strong (allopurinol and quercetin) or moderate (caffeic and gallic 
acids) inhibitors (see Cassien et al. (2016) for the two latter compounds). Table 3 shows that the 
same extracts demonstrating appreciable inhibition against XO possessed much stronger O2
-
 
scavenging activities (i.e., ~1000-fold), as indicated by considerably lower IC50 values < 0.3 
µg/mL. Strong positive correlations (P < 0.05) were obtained between O2
-
 quenching and TPC 
(r² = 0.711), TFC (r² = 0.776) and hydroxycinnamic derivatives contents (r² = 0.556), but not 
with hydroxybenzoic derivatives, suggesting the participation of phenolics constitutes of the 
extracts (and particularly hydroxycinnamates). The MCC value, an index of the capacity of 
compounds to inhibit iron-induced lipid peroxidation by forming complexes with Fe
2+
, exhibited 
strong variations among extracts, decreasing in the order: PE > AQL  methanol > ethyl acetate 
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 AR fraction  butanol (Table 3). Globally, the activities were weak to moderate as compared to 
reference compounds and negative, but not significant correlations were found between the MCC 
of extracts and TPC, TFC, or any of the peroxyl (TRAP, ORAC) and O2
-
 radicals scavenging 
activity indices tested above (r² = 0.2940.464). Of interest, an inverse correlation was observed 
between MCC and DPPH reducing activity (r² = 0.657, P < 0.05), in agreement with previous 
observations (Zhao et al., 2008), suggesting that extracts with higher MCC capacity might have 
lower scavenging activity. Notably, a negative correlation was found between MCC and HPLC-
determined flavonoid content (r = 0.853, P < 0.05) suggesting that in most of the extracts, 
flavonoids could be predominantly in a metal-flavonoid complex form, with consequently a poor 
chelating capacity but increased antioxidant and scavenging properties (Liu et al., 2015),
 
rather 
as glycoside conjugates. 
 
3.2.3. Hydroxyl radical scavenging activity of water soluble extracts 
 The HO

 inhibitory activity was first determined using a radiomimetic (with EDTA) and 
site-specific (without EDTA) deoxyribose assay in phosphate buffer, pH 7.4. All the three water 
soluble extracts showed concentration-dependent inhibition of deoxyribose oxidative degradation 
in both conditions, with a peak at ~0.25 mg/mL and a greater activity observed in the 
radiomimetic assay (Fig. 3A). The 'free' HO

 scavenging potencies, as can be estimated by 
radiomimetic assay (Halliwell et al., 1987), decreased among extracts in the following order: 
butanol  AQL > AR fraction. The iron chelation potencies, as can be estimated by the site-
specific assay (Aruoma et al., 1987), decreased among extracts in the following order: butanol > 
AQL  AR fraction, a discrepancy with the MCC data (Table 3) that could originate from 
differences in solvent and pH. At a concentration of 0.3 mg/mL all samples exhibited a marked 
reincrease of absorbance, especially under radiomimetic conditions (Fig. 3A). Such pro-oxidant 
effect in the deoxyribose assay is common to several plant-derived polyphenols and flavonoids 
such as quercetin (Puppo, 1992), and the strong potency seen in the butanol extract may be 
related to its high TPC and TFC contents (Table 1). 
 In addition, the relative rate constants for the HO

 scavenging by extracts were estimated by 
determining the slopes of plots of 1/A532 against concentration in the radiomimetic assay (Fig. 
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3B). Using that method, a rate constant of 1.9×10
9 
M
1
.s
1
 was obtained for mannitol, in 
agreement with literature data (Halliwell et al., 1987). Thus, the calculated apparent rate 
constants for butanol extract, AQL and AR fraction were of 11.2×10
9
, 9.5×10
9
 and 6.3×10
9 
M
1
.s
1
, respectively. 
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Fig. 3. Hydroxyl radical scavenging by A. radiata water soluble extracts. Values represent means ± SEM 
(n = 36). (A) Concentration-dependent effect of extracts on [Fe
3+
ascorbateH2O2] deoxyribose 
degradation in the presence (radiomimetic) or absence (site-specific) of EDTA. (B) Determination of rate 
constants for HO

 scavenging. Absorbances at 532 nm (A532) were that measured in the radiomimetic 
deoxyribose assay. (C) Kinetic competition plots for the trapping on DMPO of [Fe
2+
H2O2]-generated 
HO

 in the presence of extracts. I0 and I represent EPR signal intensities in the extract-free control and 
sample, respectively. 
 
 In a second set of experiments EPR spin-trapping was used as an alternative method to 
measure HO

 inhibitory activity. Hydroxyl radicals generated in a Fe
2+
H2O2 system were 
trapped by the spin trap DMPO to form adducts which can be detected by EPR. The signal is 
inhibited by HO

 scavengers which compete with DMPO for HO

. The results confirmed the 
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strong HO

 scavenging activities seen in the deoxyribose radiomimetic assay, with 
concentration-dependent inhibition of the EPR signals obtained up to 10 mg/mL for each extract. 
It must be pointed out that in all experiments with the butanol extract no additional signals were 
detected, e.g., secondary carbon centered adducts arising from the reaction of HO

 with residual 
n-butanol. Using an established methodology (Finkelstein et al., 1980), the apparent rate 
constants for HO

 scavenging were estimated from the slopes of the competitive kinetic plots 
shown in Fig. 3C. Compared to the scavenging potency of the butanol extract, other extracts 
appeared less efficient in the EPR assay (62% for AQL and 79% for AR fraction) vs the 
radiomimetic deoxyribose assay (15% for AQL and 44% for AR fraction). 
 
3.3. Inhibitory activities against digestive enzymes 
 
 The management of postprandial blood glucose levels using carbohydrate-hydrolyzing 
enzymes inhibitors from natural sources is considered an economically attractive therapeutic 
approach in the treatment of type 2 diabetes since the use of synthetic drugs is often associated 
with gastrointestinal adverse effects. Most studies on plant extracts or phytoconstituents that may 
contribute to diabetes treatment have focused on the inhibition of α-amylase and α-glucosidase, 
which catalyze carbohydrate digestion into glucose (De Sales et al., 2012; Etxeberria et al., 
2012). Several members belonging to the Asteraceae family were proposed as functional 
antidiabetic agents (Sidhu et al., 2013; Silva et al., 2016), a property associated with the enzyme 
inhibitory potential of their polyphenolic constituents, particularly flavonoids (Silva et al., 2016). 
 The inhibitory activities of A. radiata extracts against pancreatic α-amylase and two sources 
of α-glucosidase (SC and RIP) were evaluated. The inhibitors, voglibose, miglitol and acarbose, 
and the flavonoids of similar structure, luteolin and myricetin, were used as positive controls. 
Two assays for α-glucosidases were carried out because enzymes from different origins are 
known to strongly differ in inhibition assays due to their different structure (Oki et al., 1999). 
Table 4 shows IC50 values and the concentrations of samples associated with the maximum 
inhibition reached. The α-amylase inhibitory activities decreased among extracts in the following 
order: ethyl acetate > butanol > methanol  AQL, while the PE extract and AR fraction were 
inactive (not shown). Interestingly, a stronger inhibition of α-amylase activity was reported for 
 27 
ethyl acetate and butanol vs PE extracts of Phyllostachys edulis leaves and the authors concluded 
that high flavonoids levels contained in polar fractions could act by retarding the enzyme 
carbohydrate digestion and directly interacting with starch (Yang et al., 2014). The pronounced 
effects of acarbose and both flavonoids shown in Table 4 were in agreement with previous 
determinations under similar conditions (Oki et al., 1999; Olaokun et al., 2013; Tadera et al., 
2006), and, in connection with the flavonoids constituents of the four active extracts, a good 
correlation was found between their α-amylase inhibitory capacity and their respective TPC (r² = 
0.912, P < 0.05), TFC (r² = 0.973, P < 0.01) and hydroxycinnamic contents (r² = 0.988, P < 
0.01). 
 The SC and RIP α-glucosidase inhibitory activities decreased among extracts in the 
following order: ethyl acetate  AQL > butanol > methanol, and butanol > ethyl acetate > AQL 
>> methanol, respectively (Table 4). In both assays the PE extract and AR fraction were again 
inactive (not shown). In the SC assay, no IC50 was found for either active extract, while acarbose 
and both flavonoids, but not miglitol and voglibose, showed at least two-fold better efficiencies. 
In the RIP assay, both flavonoids were low α-glucosidase inhibitors whereas voglibose, miglitol 
and acarbose showed stronger properties in line with earlier measurements (Oki et al., 1999). 
Using a SC assay, Silva et al. (2016) reported a strong α-glucosidase SC inhibitory activity for 
the ethyl acetate extracts of Eremanthus crotonides (Asteraceae) and identified several active 
polyphenolic constituents such as quercetin, quercetin-3-methyl ether, luteolin, and 
caffeoylquinic acid n-butyl ester derivatives. However in both α-glucosidase assays performed in 
the present study, no correlation was found between the inhibition potency and the TPC and TFC 
of the extracts. 
 
3.4. Cytotoxicity studies 
 
 The cytotoxic properties of the four extracts exhibiting the highest activities in antioxidant 
and enzyme inhibition assays were screened against A549 and NHLF cells by running FMCA 
and MTT cell viability, and metabolic activity assays. Cells were incubated in DMEM 
containing 0.2% DMSO as vehicle for 48 h. Prior to experiments it was checked that addition of 
0.2% DMSO in culture medium did not induce any loss of viability of confluent cells after 
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incubation for 48 h (not shown). Results showed very low cytotoxic effects from AQL and 
butanol extract, with IC50 values > 250 µg/mL in both cell lines, NHLF being understandably 
more sensitive (Table 5). Much lesser cell viability was observed for the methanol and ethyl 
acetate extracts and, for this latter fraction, it can be proposed that cytotoxicity may be related to 
the presence of low polar constituents such as flavonoid conjugates, alkaloids, saponins or 
tannins that can interfere with cell membranes at high concentrations. 
 Altogether, the more soluble AQL and butanol extract, which demonstrated optimized 
antioxidant, enzyme inhibitory and low cytotoxic properties comparable with metformin (Table 
5), were considered suitable for further in vivo testing. 
 
3.5. Protective effect on LDL oxidation  
 
 Oxidative damage of lipid molecules is one of the initial steps in the development of 
atherosclerosis and cardiovascular diseases caused by hyperlipidemia and its prevention by 
antioxidants could be an efficient therapeutic approach. Human LDL was oxidized in vitro by 
copper ions in the presence of 530 µg/mL of AQL, butanol extract or metformin, and the 
degree of LDL oxidation was assessed by monitoring the production of conjugated dienes (at 234 
nm) for 6 h at 37 °C and TBARS formation (at 532 nm) immediately after incubation. Both 
extracts, at 5 µg/mL, but not metformin, significantly inhibited conjugated diene formation 
relative to LDL oxidized without extract (P < 0.05 by two-way ANOVA), and the kinetic 
profiles indicated a delayed lag time (> 4 h) for maximal diene formation that peaked at 4 h in 
the control (Fig. 4A). Relative to the control LDL oxidation TBARS levels were significantly 
decreased by AQL and butanol extract in a concentration-dependent manner (Fig. 4B), with IC50 
values of 7.1 µg/mL and 4.2 µg/mL, respectively. In these experiments the flavonoids quercetin 
(IC50 = 0.32 µg/mL) and luteolin (IC50 = 0.98 µg/mL), but not naringenin were more potent 
inhibitors, in line with literature data (Miranda et al., 2000). Again, metformin was ineffective as 
antioxidant in reducing LDL oxidation as compared to extracts. 
 29 
0 1 2 3 4 5 6
0.0
0.1
0.2
0.3
0.4
Cu
2+
quercetin
butanol extract
AQL
incubation time (h)
a
b
s
o
rb
a
n
c
e
 a
t 
2
3
4
 n
m
2+
C
u
qu
er
ce
tin
na
ri
ng
en
in
lu
te
ol
in
 
g/
m
L)

n-
B
uO
H
 (5
 
g/
m
L)

n-
B
uO
H
 (1
5 
g/
m
L)

 A
Q
L 
(5
 
g/
m
L)

 A
Q
L 
(1
5 m
et
fo
rm
in
0.0
0.1
0.2
0.3
0.4
0.5
***
***
***
a
b
s
o
rb
a
n
c
e
 a
t 
5
3
2
 n
m
A B
 
Fig. 4. Oxidation of human LDL (50 µg proteins/mL) upon incubation with CuSO4 (2 mM) in PBS. (A) 
Time course of the formation of conjugated dienes in the absence or presence of test compounds (5 
µg/mL). (B) TBARS levels after 6 h incubation in the absence or presence of test compounds: quercetin 
and luteolin (2 µg/mL), narigenin (25 µg/mL), metformin (25 µg/mL) or A. radiata extracts (5 or 15 
µg/mL). Values represent means ± SEM (n = 36). Statistics:
***
P < 0.001 vs Cu
2+
 (control) by one-way 
ANOVA followed by multiple comparisons tests. 
 
3.6. Protective effect on cultured rat pancreatic beta-cells in high-glucose conditions 
 
 It was evaluated whether AQL and butanol extract may promote viability and metabolic 
activity of rat INS-1E beta-cells exposed to hyperglycemic medium mimicking diabetes 
conditions. As expected, both cell viability and metabolic activity were significantly reduced to 
~50% of control values when beta-cells were exposed for 84 h to high glucose (Figs. 5A and 
5B). Cells exposed to the highest glucose concentration of 25 mM were apoptotic as evidenced 
by a ~1.5-fold enhancement of caspase-3 activity vs normal conditions (Fig. 5C). 
Hyperglycemia-induced cell damage was dose-dependently prevented by application of 115 
µg/mL of each extract (Fig. 5) suggesting that they can be effective as anti-apoptotic and 
protective agents at doses compatible with plasma concentrations as low as 5 µg/mL. 
Furthermore, these effects of extracts were comparable to that of 3 µg/mL quercetin, suggesting 
that the phenolic fraction of the extract could be central to the protective activity. 
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Fig. 5. Protective effect of A. radiata extracts against high-glucose induced toxicity in beta-cells. Cell 
viability and apoptosis were assessed by (A) MTT-based metabolic activity, (B) intracellular ATP 
content, (C) cytosolic caspase-3 activity. INS-1E cells were incubated in RPMI 1640 medium containing 
normal glucose (control, 5 mM) or high-glucose (HG, 25 mM) concentration for 84 h in the absence or 
presence of test compounds: quercetin (3 µg/mL), AQL and butanol extract (5 or 15 µg/mL) or 
[Met+AQL] (at 2 and 5 µg/mL, respectively). Statistics:
*
P < 0.05 and 
***
P < 0.001 vs control, 
§
P < 0.01 
and 
†
P <0.001 vs HG and and 
‡
P < 0.05 vs [Met+AQL], by one-way ANOVA followed by Tukey’s 
multiple comparisons tests. 
 
 Although data in Tables 2 and 3 are compatible with a poor antioxidative and scavenging 
property for metformin it yet exerted protective effect on beta-cells at 2 µg/mL, possibly by 
correcting abnormalities of intracellular calcium metabolism in insulin-sensitive tissues (Viollet 
et al., 2012). Interestingly, adding 5 µg/mL of AQL strongly enhanced this protective effect of 
metformin on beta-cell survival (Fig. 5). 
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3.7. Acute oral toxicity of extracts on C57BL/6J mice 
 
 Since none of the animals receiving orally 2000 mg/kg of AQL or butanol extract died up to 
10 days, and did not show any signs of pain, distress and suffering, it was considered that the 
LD50 is  4000 mg/kg in both cases. According to Yamanaka et al. (2010), extracts with such 
low toxicity would not require further testing for lethal effects. Therefore, next pharmacological 
investigations were carried out using the non toxic dose window of 25250 mg/kg of body 
weight, which is relevant to the use of the plant in traditional medicine (Ghourri et al., 2013). 
 
3.8. Antidiabetic effect on high-fat-fed C57BL/6J mice 
 
 The potential of plants exerting hypoglycemic and/or insulin mimetic activities to be 
developed as natural antidiabetics is increasingly exploited. Their biological activity relies on 
different mechanisms, including inhibition of carbohydrate hydrolyzing enzymes, inhibition of 
renal glucose reabsorption, insulin secretion stimulation or insulin resistance reduction, increase 
of the number and the size of cells in the islets of Langerhans, inhibition of glucose production 
and upregulation of glucose transporters or antioxidant activity (Rios et al., 2015). Although A. 
radiata has been part for a long time of Saharian traditional medicine to treat hyperglycemic 
related diseases (Bnouham et al., 2006; Hammiche and Maiza, 2006; Ghourri et al, 2013), little is 
known so far about the usefulness of the plant in treating experimental diabetes. Given the strong 
antioxidant, radical scavenging, enzyme inhibitory properties and protective activity on 
lipoproteins and pancreatic cells of AQL and butanol extract established above, their in vivo 
potential was investigated in HFD-fed C57BL/6J mice to determine (i) their dose-response acute 
hypoglycemic activity in blood within 4 h, and (ii) their anti-hyperglycemic and antidiabetic 
activity after long-term oral treatment, with the purpose to delineate the underlying mechanisms. 
 
3.8.1. Acute hypoglycemic activity of extracts: dose determination study 
 Mice on HFD for 16 weeks were given the extracts orally at 25, 75, 150 and 250 mg/kg or 
15 mg/kg glibenclamide and blood glucose levels were monitored up to 4 h post treatment. The 
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two extracts showed a potent hypoglycemic property reaching a maximum at 150 mg/kg, with an 
effect comparable to that of glibenclamide at the dose of 15 mg/kg (Fig. 6A). Therefore, 150 
mg/kg was selected for the long term in vivo studies on A. radiata extracts. 
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Fig. 6. Acute hypoglycemic effect and oral glucose tolerance test (OGTT) in mice given A. radiata 
extracts. (A) Blood glucose levels after dose-response acute oral treatment (B) Blood glucose levels 
during OGTT. (C) Area under the curve of blood glucose levels during OGTT. Treatments: control, mice 
fed with standard diet; HFD, mice on high-fat-diet for 28 weeks; +n-BuOH, mice on HFD for 16 weeks, 
followed by HFD + butanol extract (150 mg/kg) for 12 weeks; +AQL, mice on HFD for 16 weeks, 
followed by HFD + AQL (150 mg/kg) for 12 weeks; +AQL75, mice on HFD for 16 weeks, followed by 
HFD + AQL (75 mg/kg) for 12 weeks; +Met, mice on HFD for16 weeks, followed by HFD + metformin 
(150 mg/kg) for 12 weeks; +Met75+AQL75, mice on HFD for 16 weeks, followed by HFD + [metformin + 
AQL] (both at 75 mg/kg) for 12 weeks. Statistics:
*
P < 0.05, 
**
P < 0.01 and
***
P < 0.001 vs control; 
§
P < 
0.01 and 
†
P <0.001 vs HFD and 
‡
P < 0.05 vs [Met75+AQL75] group, by one-way ANOVA followed by 
Tukey’s multiple comparisons tests. 
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3.8.2. Long-term study on diabetic mice: food intake, body weight and body fat pad weight 
 At the onset of treatments the mean body weight was of 17.1 ± 1.1 g (n = 84). Table 6 shows 
that, after 28 weeks, the animals from the HFD group showed significant higher weight gain 
(+242%, corresponding to 0.85 g/week) compared to the control SD group (+175%, 
corresponding to 0.45 g/week). Once the obesity induction was characterized at 16 weeks, i.e., 
the mean weights were 30.7 ± 0.2 g in the HFD group and 22.5 ± 0.1 g in the SD group, five sub-
groups of animals from the HFD group were distributed into the [HFD+AQL], [HFD+AQL75], 
[HFD+n-BuOH], [HFD+Met] and [HDF+Met75+AQL75] groups and were additionally fed 150 
mg/kg body weight of the corresponding test compound for the remaining 12 weeks with the 
exception of [HFD+AQL75] and [HDF+Met75+AQL75] groups where the doses of AQL and Met 
were of 75 mg/kg. While in this period the HFD group continued showing higher body weight 
compared to SD group, the trend was significantly prevented in 150 mg/kg-treated groups, with 
comparable final weight gains of +200%,+198% and +199% in the [HFD+AQL], [HFD+n-
BuOH] and [HDF+Met] groups, respectively (corresponding to ~0.65 g/week in both groups; 
Table 6). At the lowest dose of 75 mg/kg, AQL still prevented the development of obesity 
(+206%) and adding metformin even improved the weight reduction (+191% in the 
[Met75+AQL75] group). At the end of treatment, the body fat mass percentage was of 10% in SD 
group, which strongly increased to 22% in HFD group, significantly decreased to only 12% in 
the [HFD+n-BuOH] and [HFD+Met75+AQL75] groups and remained within 1416% in the other 
treated groups. As no changes among groups were seen concerning food intake (Table 6), the 
difference in caloric intake in the HFD group (i.e., ~1.5-fold vs SD group) is likely responsible 
for the observed gain in body and fat mass.
 
Results in the HFD group were in accordance with 
previous reports on the susceptibility of the C57BL/6J strain to develop hyperglycemia, 
hyperinsulinemia and obesity when administered HFD containing 3060% fat. These 
characteristics have been reported appropriate to investigations of curative action of traditional 
medicines in type 2, insulin resistant diabetes (Gallou-Kabani et al., 2007; Yokota et al., 2009; 
Hamza et al., 2012). Thus, it was concluded that the two tested extracts could significantly lower 
HFD-induced increase in body weight and adiposity without affecting the caloric intake. 
 
3.8.3. Effect on blood glucose and insulin, glucose tolerance, hemoglobin glycation, 
hyperleptinemia and hyperlipidemia 
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 At the onset of treatments the baseline levels of fasting glucose and insulin were of 80.4–
82.6 mg/dL and 1.2–1.6 ng/mL, respectively, increasing by ~300% and ~270%, respectively at 
week 28 in HFD mice. Treatment with AQL or butanol extract at the dose of 150 mg/kg and, to a 
lesser extent with 75 mg/kg of AQL, significantly reduced blood glucose and moderated 
hyperinsulinemia as compared to the HFD group. Expectedly, the insulin-sensitizing agent 
metformin showed potent antihyperglycemic properties at 150 mg/kg, with a slightly better, yet 
not significative hypoglycemic effect vs AQL and butanol extract at the same dose (Table 6). 
Compared to SD mice, animals on HFD developed type 2 diabetes with characteristics of insulin 
resistance as indicated by the OGTT assay. The sustained blood glucose level seen at 90 min was 
significantly reduced by treatment with either AQL alone (150 mg/kg) or a mixture of metformin 
and AQL (both at 75 mg/kg) in a dose–dependent manner (Fig. 6B). Improvement of the overall 
glucose exposure in groups supplemented by AQL and butanol extract was evaluated by 
calculating the AUC which decreased by 34%, 33%, 22%, 48% and 55% in the AQL, butanol 
(both at 150 mg/kg), AQL75, Met (at 150 mg/kg) and [Met75+AQL75] groups, respectively (Fig. 
6C). 
 As shown in Table 6, the HbA1C content of the HFD group is significantly (P < 0.001) 
increased compared to the SD group, as a consequence of long-term high levels of circulating 
glucose that reacts with hemoglobin and other proteins. All treatments significantly decreased 
the HbA1C level towards control value, with a better efficacy exhibited by the combination of 
AQL and metformin (both at 75 mg/kg), an effect consistent with the improved property of this 
mixture in blood glucose and hyperinsulinemia normalization (Fig. 6B and 6C). 
 Further, data in Table 6 also revealed that treatments significantly improved lipid 
metabolism and accumulation in diabetic mice. Hyperleptinemia was reduced by 34.861.1%, 
circulating levels of cholesterol and triglycerides decreased by 24.041.5% and 19.637.5%, 
respectively, and triglycerides accumulation in liver tissue were dramatically reduced by 
57.975.4%. It is noteworthy that treatments based on AQL or butanol extract both strongly 
decreased adipose tissue mass and brought cholesterol and triglycerides levels close to normal 
values, suggesting that they may exert a lipolytic and/or antiadipogenic activity. In medicinal 
plants, improved anti-obesity and anti-dislipidemia efficacy has been linked to a high content of 
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hydroxycinnamic acid derivatives (Alam et al., 2016), a feature of the butanol extract developed 
here (Table 1).
 
 
Last, the liver glycogen content of HFD mice was significantly (P < 0.01) depleted 
compared to the SD group (Table 6), revealing an increase in gluconeogenic enzymes activities 
due to the altered action of insulin. All treatments and metformin strongly protected liver 
glycogen loss, a result that could be related to the ability of the antidiabetic drug to reduce 
hepatic gluconeogenesis, and improve glucose uptake and pancreatic islet cells protection 
(Viollet et al., 2012). This hypothesis appears confirmed for AQL and butanol extract owing to 
the results of the study on beta-cells (Fig. 5). 
 
3.8.4. Oxidative stress markers and inflammatory cytokines levels 
 There is a consensus that chronic hyperglycemia in type 2 diabetic subjects induces a 
cascade of pathological events, including ROS formation, antioxidant consumption, increased 
lipid peroxidation, protein oxidation and beta-cells dysfunction (Giacco and Brownlee, 2010; 
Meigs, 2010). Such increased oxidative stress status was detected in the HFD group which 
demonstrated ~30% lowered blood GSH/GSSG levels and ~70% increased formation of plasma 
protein carbonyls when compared to the SD group. Both A. radiata treatments quite completely 
(for the ratio of reduced to oxidized glutathione) or partly (protein oxidation) restored the normal 
levels (Table 6), suggesting the involvement of antioxidant mechanisms such as those found in 
vitro (Tables 2 and 3). Clinical studies reported a good correlation between elevated protein 
carbonyls levels and poor glycemic control (i.e., when HbAC1 > 7), GSH depletion, impaired 
trace elements status and lipid peroxidation (Whiting et al., 2008). Although 150 mg/kg of 
metformin produced substantial reduction in hyperglycemia and HbA1c, it did not significantly 
affect oxidative stress markers as provided by A. radiata extracts at the same dose (Table 6). As 
in the cell study, a synergistic effect of metformin with 75 mg/kg of AQL led to a normalization 
of blood GSH/GSSG ratio and protein carbonyls level. 
 Diabetes-associated oxidative stress adversely affects (i) myocardial function and structure, 
leading to diabetic cardiomyopathy and heart failure, and (ii) skeletal muscle mitochondrial 
respiration, causing impaired tolerance to exercise (Yokota et al., 2009; Meigs, 2010). In 
particular, O2
-
 release consecutive to NADPH oxidase activation has been incriminated as a 
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trigger of diabetes-induced cardiovascular and skeletal muscle pathophysiology because high 
levels of glucose, fatty acids or insulin are responsible for mitochondrial damage and impaired 
contractile capacity in muscle cells (Yokota et al., 2009; Meigs, 2010). 
 In accordance, the myocardium and hindlimb muscle of mice on HFD for 28 weeks 
exhibited a strong increase in NADPH oxidase activity as detected by lucigenin luminescence 
(Fig. 7), which was abolished when tissue was treated with the NADPH inhibitor DPI or O2
-
 
scavenger Tiron (data not shown). This NADPH-dependent O2
-
 production in both types of 
tissues of diabetic animals was strongly limited by treatment with 150 mg/kg of each extract or 
metformin, the latter being significantly less active in the myocardium (Fig. 7B). A dose-
dependent effect was found when the AQL dose was lowered to 75 mg/kg and again a better 
overall response was obtained in the [Met75+AQL75] vs AQL75 groups. 
co
nt
ro
l
 H
FD
-B
uO
H
n+
+A
Q
L
75
+A
Q
L
+M
et 75
+A
Q
L
75
+M
et
0
200
400
600
800
1000 ***
*§
**
*§
‡
†
*§
N
A
D
P
H
 o
x
id
a
s
e
 a
c
ti
v
it
y
 (
S
M
)
 (
R
L
U
/m
in
/ 
1
0
0

g
 p
ro
te
in
)
co
nt
ro
l
 H
FD
-B
uO
H
n+
+A
Q
L
75
+A
Q
L
+M
et 75
+A
Q
L
75
+M
et
0
200
400
600
800
1000
*** ‡
†
*§
N
A
D
P
H
 o
x
id
a
s
e
 a
c
ti
v
it
y
 (
M
Y
O
)
 (
R
L
U
/m
in
/ 
1
0
0

g
 p
ro
te
in
)
A B
 
Fig. 7. NADPH oxidase activity in (A) hindlimb skeletal muscle and (B) myocardial homogenates of 
mice on HFD diet treated with A. radiata extracts. Treatments: see legend of Fig. 6. Statistics:
*
P < 0.05 
and 
***
P < 0.001 vs control; 
§
P < 0.01 and 
†
P  < 0.001 vs HFD and 
‡
P < 0.05 vs [Met75+AQL75] group, by 
one-way ANOVA followed by Tukey’s multiple comparisons tests. 
 
 Another feature of metabolic syndrome associated with obesity is the establishment of a 
chronic, mild inflammatory state, with the release of inflammatory mediators that could play a 
crucial role in insulin resistance (Akash et al., 2013). Table 6 shows that both levels of cytokines 
IL-6 and TNF-α, but not MCP-1, were strongly altered in 28 weeks-HFD group mice. Of the 
tested extracts AQL demonstrated a slightly higher anti-inflammatory activity characterized by a 
better action on TNF-α. Recent studies have reported that plant extracts may serve as dual 
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hypoglycemic and anti-inflammatory material (Heyman et al., 2014), or could be used as 
hypolipidemic treatments possibly acting on cellular pathways involved in adipogenesis 
expression (Lee et al., 2014). 
 
4. Conclusion 
 
 In summary, this is the first study to rationalize the traditional use of Anvillea radiata for the 
treatment of hyperglycemia and diabetic complications. Lyophilized aqueous and butanol 
extracts of the aerial parts of the plant demonstrated strong antihyperglycemic, 
antihyperlipidemic and anti-inflammatory activity, and delayed oxidative stress induced-
myocardial and muscle damage C57BL/6J mice selected because they undergo type 2 diabetes 
similar to humans upon high-fat diet (Fröde and Medeiros, 2008). Since this genetically modified 
animal model has some limitations, additional in vitro studies were performed to investigate 
complementary potential molecular mechanisms of action that may support the effectiveness of 
the plant in humans. Among them, inhibition of α-amylase and α-glucosidase, antioxidant and 
free radical scavenging, and protection of pancreatic beta-cells were identified. The two extracts 
also exhibited strong insulin sensitizing effects comparable to that of metformin. The current 
results will be useful for assessing the benefit of A. radiata extracts in the treatment of diabetic 
neuropathy, a major complication associated with mitochondrial dysfunction, oxidative stress 
and inflammatory mediated damage in neurons and glial cells (Sandireddy et al., 2014; Singh et 
al., 2015). To this purpose, more specific protocols allowing the monitoring of peripheral nerve 
conduction velocity and injury are available (Yadav et al., 2014; Yang et al., 2015). More 
generally, it is believed that A. radiata-derived material is particularly suitable for developing a 
neutraceutical for the management of type 2 diabetes and obesity or for add-on therapy with 
metformin. 
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Glossary 
 
AAPH, azobis(2-amidinopropane) dihydrochloride; AQL, lyophilized aqueous extract; AR, 
aqueous residual; CNPG3, 2-chloro-4-nitrophenol-α-D-maltotrioside; DMEM, Dulbecco’s 
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modified Eagle’s medium; DMPO, 5,5-dimethyl-1-pyrroline N-oxide; DPI, 
diphenyleneiodonium; DPPH, 2.2-diphenyl-1-picrylhydrazyl; DTPA, 
diethylenetriaminepentaacetic acid; EPR, electron paramagnetic resonance; FBM, fibroblast 
basal medium; FGM, fibroblast growth medium; FMCA, fluorometric microculture cytotoxicity 
assay; GSH, reduced glutathione; GSSG, oxidized glutathione; Hb, hemoglobin; HbA1C, 
glycosylated hemoglobin; HFD, high-fat diet; IL-6, interleukin-6; MCC, metal chelating 
capacity; MCP-1, monocyte-chemoattractant protein 1; Met, metformin; MTT, 3-(4,5-dimethyl-
2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide; NBDH, 7-hydrazino-4-nitrobenzo-2,1,3-
oxadiazole; NHLF, human normal lung fibroblasts; OGTT, oral glucose tolerance test; ORAC, 
oxygen radical absorbing capacity; PE, petroleum ether; pNPG, p-nitrophenyl-α-D-
glucopyranoside; PPA, porcine pancreatic α-amylase; RIP, rat intestinal acetone powder; ROS, 
reactive oxygen species; RPMI, Roswell Park Memorial Institute medium; SD, standard diet; 
TBA, 2-thiobarbituric acid; TBARS, thiobarbituric acid-reactive substances; TFC, total 
flavonoid content; TNF-α, tumor necrosis factor-α; TPC, total phenolic content; TRAP, total 
radical antioxidant potential; XO, xanthine oxidase. 
 
 
Table 1 Total phenolic (TPC), total flavonoid (TFC) contents and concentrations of phenolic 
compounds
a
 in A. radiata extracts detected by HPLC-DAD. 
Extract
b
     Major phenolic compounds 
  TPC TFC TFC/TPC Hydroxycinnam
ic 
Flavonoid
s 
Hydroxybenzo
ic 
 (mg 
GAE
c
/g
) 
(mg 
RUE/g
) 
 derivative
s (mg 
CAE/g) 
(mg RUE/g) derivative
s (mg 
GAE/g) 
 
AQL 77.4 ± 
3.5* 
32.5 ± 
0.3* 
0.42 
± 
0.03 
17.89 ± 
1.07* 
13.28 ± 1.23* 1.41 ± 
0.09* 
 
methanol 65.8 ± 
1.8* 
48.4 ± 
0.9* 
0.74 
± 
0.04
* 
24.10 ± 
1.44* 
29.01 ± 2.63
#
 3.05 ± 
0.20
#
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petroleu
m ether 
29.9 ± 
1.2
§
 
15.5 ± 
0.6
§
 
0.51 
± 
0.04 
4.05 ± 
0.38
§
 
1.73 ± 0.10
§
 0.47 ± 
0.03
§
 
 
ethyl 
acetate 
158.9 ± 
5.3
‡
 
63.1 ± 
1.8
#
 
0.40 
± 
0.05 
90.91 ± 
5.16
‡
 
66.82 ± 13.81
‡
 nd
d
  
n-
butanol 
122.5 ± 
3.2
#
 
59.6 ± 
1.1
#
 
0.48 
± 
0.02 
56.38 ± 
3.20
#
 
39.65 ± 2.85
#
 3.6 ± 
0.23
#
 
 
AR 
fraction 
36.9 ± 
1.3
§
 
8.3 ± 
0.1
§
 
0.22 
± 
0.01
§
 
6.68 ± 
0.40
§
 
nd nd  
 
a
Values are expressed per gram of extract and represent the mean ± SEM of 3–6 independent 
experiments made in triplicate. 
b
AQL, lyophilized aqueous extract; AR, aqueous residual. 
c
GAE, 
gallic acid equivalents; RUE, rutin equivalents; CAE, caffeic acid equivalents.
 d
nd: not detected. 
Statistics: the same symbols *, 
§
, 
# 
or 
‡
 indicate that values are significantly different (P < 0.02) 
from others by one-way ANOVA followed by Newman-Keuls multiple comparisons test. 
 
Table 2 Antioxidant capacities
a
 in the DPPH, ORAC and TRAP assays. 
Extract or DPPH  ORAC TRAP 
compound     
 IC50 (µg/mL) TIC50 (min)
b
 (µmole 
TE
c
/g) 
(µmole 
TE/g) 
     
AQL 130.3 ± 4.3* 23.7* 1390 ± 
50* 
512.4 ± 
21.2* 
methanol 140.3 ± 5.2* 46.1 1475 ± 
95* 
498.5 ± 
19.9
*
 
petroleum ether 518.7 ± 35.7
§
 42.7 363 ± 
11
§
 
15.3 ± 
4.2
§
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ethyl acetate 43.5 ± 0.1
#
 22.6* 3900 ± 
20
‡
 
935.0 
±


#
 
n-butanol 47.9 ± 2.6
#
 24.6* 3315 ± 
98
#
 
787.7 ± 
45.2
#
 
AR fraction 283.3 ± 25.1
§
 59.3 503 ± 
69
§
 
32.9 ± 
6.8
§
 
metformin > 500  ~0.02 ~0.02 
__________________________________________________________________________ 
a
Values represent the mean ± SEM of 3–6 independent experiments made in triplicate. 
b
Time to 
reach the steady state at IC50. 
c
Trolox equivalent. Statistics: the same symbols *, 
§
, 
# 
or 
‡
 indicate 
that values are significantly different (P < 0.02) from others by one-way ANOVA followed by 
Newman-Keuls multiple comparisons test. 
 
Table 3 Xanthine oxidase (XO) inhibition, superoxide quenching, and metal chelating capacity 
(MCC)
a
. 
 
Extract or XO inhibition Superoxide quenching MCC 
compound IC50 (µg/mL) IC50 (µg/mL) (µmol EDTAE/g)
b
 
AQL 531.0 ± 6.1* 0.222 ± 0.005* 40.1 ± 4.3* 
methanol 309.3 ± 8.7
†
 0.267 ± 0.007* 35.4 ± 4.7* 
petroleum ether > 2400
§
 0.694 ± 0.018
§
 70.9 ± 9.2* 
ethyl acetate 120.3 ± 8.2
#
 0.145 ± 0.005
#
 15.2 ± 0.9
#
 
n-butanol 352.0 ± 8.7
†
 0.186 ± 0.009
#
 10.0 ± 1.4
#
 
AR fraction > 2400
§
 0.554 ± 0.005
§
 19.0 ± 0.7
#
 
caffeic acid 19.5 ± 2.1
‡
 0.013 ± 0.000
‡
 123.4 ± 1.9
†
 
quercetin 4.2 ± 0.2
‡
 0.083 ± 0.006
‡
 102.1 ± 1.2
‡
 
gallic acid 41.1 ± 1
‡
 0.002 ± 0.000
‡
 88.2 ± 1.8
‡
 
allopurinol 1.1 ± 0.1 ––– ––– 
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metformin > 1000 > 100 ––– 
____________________________________________________________________________ 
a
Values represent the mean ± SEM of 3–6 independent experiments made in triplicate. 
b
EDTA 
equivalent. Statistics: the same symbols *, 
§
, 
# 
, 
‡
 or 
†
 indicate that values are significantly 
different (P < 0.05) from others by one-way ANOVA followed by Newman-Keuls multiple 
comparisons test.
 
 
Table 4 Inhibitory activities against porcine pancreatic α-amylase (PPA) and α-glucosidases 
from S. cerevisiae (SC) and rat intestinal acetone powder (RIP)
a
. 
Extract or α-amylase (PPA) α-glucosidase (SC) α-glucosidase (RIP) 
compound       
 IC50 (µg/mL) Inhibition (%)
b
 IC50 
(µg/mL) 
Inhibition 
(%)
c
 
IC50 
(µg/mL) 
Inhibition 
(%)
d
 
AQL nm
e
 27.7 ± 2.4* nm 34.6 ± 
1.7* 
992 ± 
40* 
50.5 ± 
1.0* 
methanol nm 35.9 ± 2.9* nm 17.7 ± 
3.1
§
 
nm 18.3 ± 
0.1
§
 
ethyl 
acetate 
135.7 ± 12.4
§
 89.3 ± 3.2
§
 nm 38.3 ± 
6.1* 
837 ± 
25
§
 
73.2 ± 
7.8
#
 
n-butanol 254.7 ± 5.2
#
 55.2 ± 1.2
#
 nm 24.8 ± 
3.1
#
 
561 ± 
53
#
 
64.5 ± 
2.1 
acarbose 0.57 ± 0.03 > 99 114.4 ± 
3.9 
63.7 ± 
2.2 
18.9 ± 
0.1 
62.4 ± 
2.6 
luteolin 4.58 ± 0.52 > 99 8.8 ± 0.4 84.6 ± 
0.8 
nm 17.1 ± 
1.9 
myricetin 7.31 ± 0.54 61.2 ± 2.8 5.2 ± 0.4 89.5 ± 
1.6 
nm 25.3 ± 
1.1 
miglitol nm 24.9 ± 4.6 nm 20.6 ± 
2.2 
19.6 ± 
0.1 
67.3 ± 
1.8 
voglibose nm 23.5 ± 2.9 nm 12.5 ± 0.35 ± 70.9 ± 
 48 
3.0 0.05 1.1 
metformin nm 12.8 ± 1.7 nm 14.3 ± 
2.0 
nm 11.2 ± 
0.9 
 
Table 4 (continued) 
a
Values represent the mean ± SEM of 3–5 independent experiments made in triplicate.
 
b
Concentrations giving maximal inhibition: extracts, 286 µg/mL; acarbose, 6.2 µg/mL;
 
luteolin 
and myricetin, 42 µg/mL; miglitol, voglibose and metformin, 62 µg/mL. 
c
Concentrations giving 
maximal inhibition: extracts, 1.4 mg/mL; acarbose, 274 µg/mL;
 
luteolin and myricetin, 20 
µg/mL; miglitol, voglibose and metformin, 42 µg/mL. 
d
Concentrations giving maximal 
inhibition: extracts, 1.0 mg/mL; acarbose, 93 µg/mL;
 
miglitol and voglibose, 3 µg/mL, 
metformin, 42 µg/mL. 
e
not measurable. Statistics: the same symbols *, 
§
 or 
#
 indicate that values 
are significantly different (P < 0.05) from others by one-way ANOVA followed by Newman-
Keuls multiple comparisons test. 
 
Table 5 Cytotoxicity against human lung cancer cells (A549) and normal fibroblasts (NHLF)
a
. 
Extract or MTT  FMCA  
compound IC50 (µg/mL)
b
  IC50 (µg/mL)  
 A549 NHLF A549 NHLF 
AQL 360 ± 12* 270 ± 13* 365 ± 21* 252 ± 6* 
methanol 143 ± 2
§
 35 ± 3
§
 123 ± 2
§
 23 ± 1
§
 
ethyl 
acetate 
118 ± 2
#
 24 ± 1
#
 108 ± 2
#
 17 ± 2
# 
n-butanol > 400 > 400 > 400 > 400 
metformin > 400 > 400 > 400 > 400 
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a
Values represent the mean ± SEM of 4–8 independent experiments made in triplicate. 
b
IC50 is 
defined as the concentration of sample resulting in 50% cell viability after 48 h and calculated 
from concentration-response curves. Statistics: the same symbols *, 
§
 or 
# 
indicate that values are 
significantly different (P < 0.05) from others by one-way ANOVA followed by Newman-Keuls 
multiple comparisons test. 
 
Table 6 Antidiabetic, antioxidant and anti-inflammatory effects of treatments in C57BL/6J 
mice
a
. 
 
Parameters Experimental groups
b
 
 Control SD HFD [HFD+AQL] [HFD+AQL75] [HF+n-BuOH] [HFD+Met] [HFD+Met75+AQL75] 
Body weight 
(g) 
29.8 ± 
0.8 
41.9 ± 
1.0*** 
34.8 ± 
0.9*
†
 
35.8 ± 
1.0*
†‡
 
33.6 ± 
0.9*
†
 
33.9 ± 
0.4*
†
 
31.7 ± 0.7
†
 
Food intake 
(g)
c
 
286 ± 6 279 ± 12 281 ± 9 282 ± 4 285 ± 8 283 ± 1 285 ± 3 
Total fat mass 
(g) 
2.91 ± 
0.03 
8.99 ± 
0.12* 
4.87 ± 
0.04*
§
 
5.31 ± 
0.08*
§
 
4.07 ± 
0.18*
†
 
4.61 ± 
0.07*
§
 
3.71 ± 0.06
†
 
Glucose 
(mg/dL) 
85.9 ± 
1.3 
260.4 ± 
7.4*** 
135.7± 
4.4*
†‡
 
143.5 ± 
3.8
†‡
 
137.0 ± 
19.8*
†
 
124.2± 
2.5*
†
 
107.5 ± 2.3
†
 
Insulin 
(ng/mL) 
1.8 ± 0.2 4.8 ± 
0.5*** 
3.1 ± 0.4
†
 3.3 ± 
0.3*
†
 
2.7 ± 0.2
†
 2.5 ± 0.3
†
 2.2 ± 0.2
†
 
HbA1C (%)
d
 5.1 ± 0.1 8.6 ± 
0.3*** 
5.9 ± 0.3
†
 6.3 ± 
0.2*
†
 
5.8 ± 0.1
†
 5.8 ± 0.2
†
 5.3 ± 0.2
† 
Leptin 
(ng/mL) 
7.1 ± 1.2 36.8 ± 
2.3*** 
15.8 ± 
1.3*
†
 
18.7 ± 
1.7*
†
 
15.3 ± 
2.2
†
 
24.0 ± 
1.9*
†‡
 
14.3 ± 1.1
†
 
T-cholesterol 
(mg/dL) 
53.8 ± 
5.8 
115.8 ± 
6.5*** 
76.8 ± 
1.2**
†
 
88.0 ± 
3.8**
§
 
67.8 ± 
2.3
†
 
85.4 ± 
3.7**
†
 
80.1 ± 3.9**
† 
 50 
Triglycerides 
(mg/dL) 
64.9± 2.1 111.7 ± 
9.5*** 
82.1 ± 
5.1
†
 
89.8± 
3.9**
§
 
69.8 ± 
3.6
†
 
78.3 ± 
2.2
†
 
72.7 ± 3.9
†
 
Triglycerides 
in 
0.69 ± 
0.04 
6.96 ± 
1.00*** 
2.59 ± 
0.45
†
 
2.93 ± 
0.31*
§
 
1.99 ± 
0.29
†
 
2.09 ± 
0.23
†
 
1.71 ± 0.24
†
 
liver tissue (mg/g) 
Table 6 (continued) 
 
Glycogen in 
liver 
49.2 ± 
2.9 
19.1 ± 
2.9** 
38.3 ± 3.5
†
 35.4 ± 6.1*
§
 31.4 ± 
6.1*
§
 
40.3 ± 3.5
§
 45.3 ± 
4.1
†
 
tissue (mg/100 
g) 
       
GSH/GSSG 3.01 ± 
0.07 
2.08 ± 
0.16*** 
2.99 ± 
0.05
†
 
2.68 ± 0.09
§
 2.65 ± 
0.16
§
 
2.19 ± 
0.11*
‡
 
3.12 ± 
0.08
†
 
PC 0.99 ± 
0.11 
1.67 ± 
0.12*** 
1.18 ± 
0.12
§
 
1.26 ± 0.11
§
 1.23 ± 
0.10
§
 
1.48 ± 
0.05
‡
 
1.09 ± 
0.03
†
 
(nmol/mg 
proteins) 
       
IL-6 (pg/mL) 9.9 ± 1.0 23.1 ± 
0.9** 
14.0 ± 1.9
†
 16.6 ± 2.1*
†
 14.6 ± 
2.0
†
 
16.9 ± 
1.3*
†
 
12.1 ± 
1.0
†
 
MCP-1 
(pg/mL) 
48.2 ± 
5.3 
55.7 ± 4.4 45.3 ± 7.2 51.0 ± 5.1 56.0 ± 
8.1 
48.3 ± 2.2 50.0 ± 
4.1 
TNF-α 
(pg/mL) 
43.5 ± 
1.9 
87.3 ± 
4.9** 
56.3 ± 3.5
†
 61.4 ± 6.1*
§
 65.4 ± 
6.1*
§
 
59.9 ± 6.3
†
 51.4 ± 
6.1
§ 
 
______________________________________________________________________________
______________________________ 
a
Values represent the mean ± SEM of 6–12 independent experiments made in triplicate. Assays 
were performed in blood plasma unless otherwise noted. 
b
Groups and treatments: SD, control 
mice fed a standard diet; HFD, mice fed a high-fat diet (60% fat); AQL, lyophilized aqueous 
 51 
extract; n-BuOH, butanol extract, Met, metformin. Extracts and metformin were administered at 
150 mg/kg/day for 12 weeks consecutive to an HFD induction of 16 weeks, except for groups 
with AQL75 and Met75 for which the doses were 75 mg/kg/day. 
c
Average food consumed per 
mouse pooled over 12 weeks. 
d
Abbreviations: HbA1C, glycosylated hemoglobin; T-cholesterol, 
total cholesterol; GSH/GSSG; ratio of reduced-to-oxidized glutathione; PC, protein carbonyls; 
IL-6, interleukin-6; MCP-1, monocyte-chemoattractant protein 1; TNF-α, tumor necrosis factor-
α. Statistics:

values are significantly different from controls (*P < 0.05, **P < 0.01and ***P < 
0.001), HFD (
§
P < 0.05 and 
†
P < 0.001) and 
‡
P < 0.05 vs [Met75+AQL75], by one-way ANOVA 
followed by Tukey’s multiple comparison test. 
